CD8A and neoplasm: In NAFLD-HCC, targeting METTL3 with single-stranded RNA, nanoparticle siRNA, or drug inhibitors (STM2457) in combination with anti-PD-1 agents can synergistically activate cytotoxic CD8+ T cells and mediate tumor regression 132.